Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16956712 | 0.85 | HDAC4 (0.40) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL3137016 | 0.81 | HDAC4 (0.43) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL2184396 | 0.77 | IDO1 (0.40) | IDO1TDO2CYP2C19SMN1; SMN2 | |
| SCHEMBL4022595 | 0.76 | CYP2C19 (0.68) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL21551717 | 0.75 | GABBR2 (0.39) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL13945718 | 0.75 | CYP2C19 (0.49) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL9003499 | 0.74 | CYP2C19 (0.55) | CYP2C19SMN1; SMN2 | |
| SCHEMBL11077274 | 0.74 | IDO1 (0.52) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL13263062 | 0.74 | HDAC4 (0.47) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL10311198 | 0.74 | AOC3 (0.45) | HDAC4HDAC7HDAC5IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378218-B2 | Cyclopentane compounds | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| CN-112424182-B | Cyclopentane compounds | 迪哲(江苏)医药股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3790870-B1 | CYCLOPENTANE COMPOUNDS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20220194922-A1 | CYCLOPENTANE COMPOUNDS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-23 | — | — | US | disclosed |
| US-11274091-B2 | Cyclopentane compounds | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-03-15 | — | — | US | disclosed |
| CN-112424182-A | Cyclopentane compounds | 迪哲(江苏)医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378218-B2 | Cyclopentane compounds | CYP11B2, CYP11B1, SQLE | HDAC4 4566/4885HDAC7 4319/4885HDAC5 3478/4885 |
| US-20220194922-A1 | CYCLOPENTANE COMPOUNDS | CYP11B2, CYP11B1, SQLE | HDAC4 4566/4885HDAC7 4319/4885HDAC5 3478/4885 |
| US-11274091-B2 | Cyclopentane compounds | CYP11B2, CYP11B1, SQLE | HDAC4 4566/4885HDAC7 4319/4885HDAC5 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.